Form 8-K - Current report:
SEC Accession No. 0001171843-25-005265
Filing Date
2025-08-11
Accepted
2025-08-11 07:10:53
Documents
12
Period of Report
2025-08-11
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_081125.htm   iXBRL 8-K 22357
  Complete submission text file 0001171843-25-005265.txt   187415

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE bcrx-20250811.xsd EX-101.SCH 3029
3 XBRL LABEL FILE bcrx-20250811_lab.xml EX-101.LAB 34239
4 XBRL PRESENTATION FILE bcrx-20250811_pre.xml EX-101.PRE 22368
14 EXTRACTED XBRL INSTANCE DOCUMENT f8k_081125_htm.xml XML 3670
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)